Holen Sie sich die Stockscreener-App
14.55
3.00%
-0.45
Handel nachbörslich:
14.55
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
Franklin Resources Inc. Has $12.31 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Truist Financial Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price - Defense World
AnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co. - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Wellington Management Group LLP Grows Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio shares target cut, hold rating kept on trial failure By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Shares Gap UpHere's What Happened - MarketBeat
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings) - Benzinga
AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout - Seeking Alpha
Truist Financial Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $20.00 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Up 9.1%Here's What Happened - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Sees Significant Growth in Short Interest - Defense World
Short Interest in AnaptysBio, Inc. (NASDAQ:ANAB) Grows By 5.8% - MarketBeat
Wedbush Has Negative Forecast for AnaptysBio FY2024 Earnings - MarketBeat
Analysts Set Expectations for AnaptysBio FY2024 Earnings - MarketBeat
AnaptysBio FY2024 EPS Estimate Increased by HC Wainwright - Defense World
Guggenheim Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $36.00 - Defense World
Q1 Earnings Forecast for AnaptysBio Issued By HC Wainwright - Defense World
Charles Schwab Investment Management Inc. Has $5.37 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio stock hits 52-week low at $14.2 amid market shifts - Investing.com Australia
AnaptysBio (NASDAQ:ANAB investor three-year losses grow to 55% as the stock sheds US$261m this past week - Simply Wall St
AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated - MSN
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals - MSN
AnaptysBio shares target cut, maintains Buy rating on phase study results - Investing.com UK
HC Wainwright & Co. Downgrades AnaptysBio (ANAB) - MSN
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints - Yahoo Finance
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio stock hits 52-week low at $14.2 amid market shifts By Investing.com - Investing.com South Africa
AnaptysBio reports failed Phase 2B trial, maintains cash reserves By Investing.com - Investing.com Canada
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data - Yahoo Finance
Anaptys scraps development of ANB032, stock plunges 33% - MSN
AnaptysBio drops development of ANB032 following trial miss - The Pharma Letter
Anaptys Announces Phase 2B Trial of ANB032, A Btla Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - Marketscreener.com
AnaptysBio to abandon eczema drug development after mid-stage trial failure - Reuters.com
Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall - MarketWatch
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - The Manila Times
Anaptysbio (ANAB) Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - StreetInsider.com
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in - EIN News
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Frazier Life Sciences Management L.P. - MarketBeat
Point72 Asset Management L.P. Buys 36,300 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Verition Fund Management LLC Acquires Shares of 22,036 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
JP Morgan Upgrades AnaptysBio (ANAB) - MSN
BNP Paribas Financial Markets Purchases 65,027 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Intech Investment Management LLC Invests $229,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Fmr LLC Purchases 438,557 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Parkman Healthcare Partners LLC Reduces Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
BTIG Downgrades AnaptysBio (ANAB) - MSN
AnaptysBio (NASDAQ:ANAB) Lowered to “Neutral” Rating by BTIG Research - Defense World
BTIG cuts AnaptysBio shares to neutral on high-risk trial setup - Investing.com Canada
Key Takeaways From AnaptysBio Analyst Ratings - Inkl
AnaptysBio (NASDAQ:ANAB) Lowered to "Neutral" Rating by BTIG Research - MarketBeat
Walleye Capital LLC Acquires New Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
How to Take Advantage of moves in (ANAB) - Stock Traders Daily
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance
Jennison Associates LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Victory Capital Management Inc. Boosts Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):